A US health regulator has approved Johnson & Johnson’s Uterapia in combination with other chemotherapy drugs for the first-line treatment of lung cancer. The FDA has approved J&J’s Rybrevant combination therapy with carboplatin and pemetrexed for patients with non-small cell lung cancer.